Ferozsons Laboratories Ltd 2022 AR2
The report highlights Ferozsons Laboratories Limited's performance and activities for the fiscal year ended June 30, 2022, marking its 66th edition. The company expanded its product portfolio with new launches in cardiology, gastroenterology, and diabetes, including the first Ertugliflozin brand in Pakistan. Ferozsons also continued its community care initiatives, such as partnering with Rizq to combat hunger, supporting the National Outreach Programme at LUMS, and collaborating with Umang for mental health counseling. Additionally, the company demonstrated its commitment to the UN Sustainable Development Goals, particularly in gender equality with three women on its seven-member Board of Directors.
Company: Ferozsons Laboratories Ltd
Sector: Health Care
Country: Pakistan
Year: 2022
Type: AR2
Pages: 200
Ferozsons Laboratories Ltd
Annual Report
The report highlights Ferozsons Laboratories Limited's performance and activities for the fiscal year ended June 30, 2022, marking its 66th edition. The company expanded its product portfolio with new launches in cardiology, gastroenterology, and diabetes, including the first Ertugliflozin brand in Pakistan. Ferozsons also continued its community care initiatives, such as partnering with Rizq to combat hunger, supporting the National Outreach Programme at LUMS, and collaborating with Umang for mental health counseling. Additionally, the company demonstrated its commitment to the UN Sustainable Development Goals, particularly in gender equality with three women on its seven-member Board of Directors.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jul 1, 2021 - Jun 30, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees